OBJECTIVE: To test the hypothesis that valvular calcium deposition, pro-osteogenic signaling, and function can be altered in mice with advanced aortic valve disease. METHODS AND RESULTS: "Reversa" mice were given a Western-type diet for 12 months and screened for the presence of aortic valve stenosis. Mice with advanced valve disease were assigned to 1 of 2 groups: (1) those with continued progression for 2 months and (2) those with regression for 2 months, in which lipid lowering was accomplished by a genetic switch. Control mice were normocholesterolemic for 14 months. Mice with advanced valve disease had massive valvular calcification that was associated with increases in bone morphogenetic protein signaling, Wnt/β-catenin signaling, and markers of osteoblastlike cell differentiation. Remarkably, reducing plasma lipids with a genetic switch dramatically reduced markers of pro-osteogenic signaling and significantly reduced valvular calcium deposition. Nevertheless, despite a marked reduction in valvular calcium deposition, valve function remained markedly impaired. Phosphorylated Smad2 levels and myofibroblast activation (indexes of profibrotic signaling) remained elevated. CONCLUSIONS: Molecular processes that contribute to valvular calcification and osteogenesis remain remarkably labile during the end stages of aortic valve stenosis. Although reductions in valvular calcium deposition were not sufficient to improve valvular function in the animals studied, these findings demonstrate that aortic valve calcification is a remarkably dynamic process that can be modified therapeutically, even in the presence of advanced aortic valve disease.
OBJECTIVE: To test the hypothesis that valvular calcium deposition, pro-osteogenic signaling, and function can be altered in mice with advanced aortic valve disease. METHODS AND RESULTS: "Reversa" mice were given a Western-type diet for 12 months and screened for the presence of aortic valve stenosis. Mice with advanced valve disease were assigned to 1 of 2 groups: (1) those with continued progression for 2 months and (2) those with regression for 2 months, in which lipid lowering was accomplished by a genetic switch. Control mice were normocholesterolemic for 14 months. Mice with advanced valve disease had massive valvular calcification that was associated with increases in bone morphogenetic protein signaling, Wnt/β-catenin signaling, and markers of osteoblastlike cell differentiation. Remarkably, reducing plasma lipids with a genetic switch dramatically reduced markers of pro-osteogenic signaling and significantly reduced valvular calcium deposition. Nevertheless, despite a marked reduction in valvular calcium deposition, valve function remained markedly impaired. Phosphorylated Smad2 levels and myofibroblast activation (indexes of profibrotic signaling) remained elevated. CONCLUSIONS: Molecular processes that contribute to valvular calcification and osteogenesis remain remarkably labile during the end stages of aortic valve stenosis. Although reductions in valvular calcium deposition were not sufficient to improve valvular function in the animals studied, these findings demonstrate that aortic valve calcification is a remarkably dynamic process that can be modified therapeutically, even in the presence of advanced aortic valve disease.
Authors: Hsiao D Lieu; Shannon K Withycombe; Quinn Walker; James X Rong; Rosemary L Walzem; Jinny S Wong; Robert L Hamilton; Edward A Fisher; Stephen G Young Journal: Circulation Date: 2003-03-11 Impact factor: 29.690
Authors: Jennifer L Hunt; Ronald Fairman; Marc E Mitchell; Jeffrey P Carpenter; Michael Golden; Tigran Khalapyan; Megan Wolfe; David Neschis; Ross Milner; Benjamin Scoll; Anita Cusack; Emile R Mohler Journal: Stroke Date: 2002-05 Impact factor: 7.914
Authors: Marcello Rattazzi; Brian J Bennett; Florian Bea; Elizabeth A Kirk; Jerry L Ricks; Mei Speer; Stephen M Schwartz; Cecilia M Giachelli; Michael E Rosenfeld Journal: Arterioscler Thromb Vasc Biol Date: 2005-04-21 Impact factor: 8.311
Authors: E S Houslay; S J Cowell; R J Prescott; J Reid; J Burton; D B Northridge; N A Boon; D E Newby Journal: Heart Date: 2006-01-31 Impact factor: 5.994
Authors: S Joanna Cowell; David E Newby; Robin J Prescott; Peter Bloomfield; John Reid; David B Northridge; Nicholas A Boon Journal: N Engl J Med Date: 2005-06-09 Impact factor: 91.245
Authors: Carolyn M Roos; Michael Hagler; Bin Zhang; Elise A Oehler; Arman Arghami; Jordan D Miller Journal: Am J Physiol Heart Circ Physiol Date: 2013-08-30 Impact factor: 4.733
Authors: Nalini M Rajamannan; Frank J Evans; Elena Aikawa; K Jane Grande-Allen; Linda L Demer; Donald D Heistad; Craig A Simmons; Kristyn S Masters; Patrick Mathieu; Kevin D O'Brien; Frederick J Schoen; Dwight A Towler; Ajit P Yoganathan; Catherine M Otto Journal: Circulation Date: 2011-10-18 Impact factor: 29.690
Authors: Yoginee Sritharen; Maurice Enriquez-Sarano; Hartzell V Schaff; Grace Casaclang-Verzosa; Jordan D Miller Journal: Physiology (Bethesda) Date: 2017-05
Authors: Jonathan D Cheek; Elaine E Wirrig; Christina M Alfieri; Jeanne F James; Katherine E Yutzey Journal: J Mol Cell Cardiol Date: 2012-01-10 Impact factor: 5.000
Authors: Yi Chu; Donald D Lund; Robert M Weiss; Robert M Brooks; Hardik Doshi; Georges P Hajj; Curt D Sigmund; Donald D Heistad Journal: Arterioscler Thromb Vasc Biol Date: 2013-01-03 Impact factor: 8.311